FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967676574> ?p ?o ?g. }

• W2967676574 endingPage "1145" @default.
• W2967676574 startingPage "1145" @default.
• W2967676574 abstract "Non-small-cell lung cancer, histologically classified into adenocarcinoma (AD) and squamous cell carcinoma, is one of the most deadly malignancies worldwide. Lung AD (LUAD) could benefit of a plethora of target therapies and, in the last few years, also of immunotherapies. Here we focused on a real-life cohort of LUAD and The Cancer Genome Atlas (TCGA)-LUAD dataset aiming to gain insights into the immune contexture of such a malignancy. We explored the mutational status of 41 genes and the expression of 94 genes, related to immune-checkpoint, inflammation, and stromal microenvironment. Surprisingly, we found that our cohort has a very low mutational burden if we consider our panel as its surrogate. Regarding gene expression data, we identified 31 genes significantly deregulated in tumor tissues compared with a pool of normal samples. Unsupervised hierarchical clustering of the deregulated genes is able to identify two clusters of tumor samples, differently enriched in alterations in actionable genes. In particular, we identified a cluster enriched in patients carrying KRAS alterations. In silico deconvolution, that is the inferring of tumor microenvironment composition by gene expression data, through TIMER algorithm has been performed to explore immune microenvironment. Estimation performed on our gene expression matrix showed that B cell infiltration is lower in the KRAS-mutated enriched cluster, as in the TCGA-LUAD dataset. Such a finding has been validated in situ through immunohistochemistry in an independent cohort. Moreover, cases in LUAD-TCGA with low B cell infiltration have a significantly worse overall survival than those with higher levels. In the real-life cohort we observed that cases belonging to cluster enriched in KRAS-mutated patients have a poor outcome. LUAD driven by KRAS mutation represents an unmet clinical need, being refractory to pharmacological inhibition. Our results link KRAS mutations to B cell infiltration. Thus, the present findings could be helpful in a better definition of immunotherapeutic approaches for KRAS mutated patients." @default.
• W2967676574 created "2019-08-22" @default.
• W2967676574 creator A5022500207 @default.
• W2967676574 creator A5024342569 @default.
• W2967676574 creator A5034916208 @default.
• W2967676574 creator A5035608148 @default.
• W2967676574 creator A5037048847 @default.
• W2967676574 creator A5044503703 @default.
• W2967676574 creator A5047645174 @default.
• W2967676574 creator A5049353036 @default.
• W2967676574 creator A5053642255 @default.
• W2967676574 creator A5056804941 @default.
• W2967676574 creator A5057663273 @default.
• W2967676574 creator A5080124352 @default.
• W2967676574 date "2019-08-09" @default.
• W2967676574 modified "2023-10-02" @default.
• W2967676574 title "KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy" @default.
• W2967676574 cites W1498673086 @default.
• W2967676574 cites W1584673858 @default.
• W2967676574 cites W1974176583 @default.
• W2967676574 cites W1985987855 @default.
• W2967676574 cites W1991874467 @default.
• W2967676574 cites W1995824006 @default.
• W2967676574 cites W2005984360 @default.
• W2967676574 cites W2020506823 @default.
• W2967676574 cites W2024384252 @default.
• W2967676574 cites W2033546181 @default.
• W2967676574 cites W2037139573 @default.
• W2967676574 cites W2042174530 @default.
• W2967676574 cites W2063270450 @default.
• W2967676574 cites W2070943369 @default.
• W2967676574 cites W2085605492 @default.
• W2967676574 cites W2090990155 @default.
• W2967676574 cites W2096385955 @default.
• W2967676574 cites W2099900951 @default.
• W2967676574 cites W2145411470 @default.
• W2967676574 cites W2164658014 @default.
• W2967676574 cites W2166923287 @default.
• W2967676574 cites W2179438025 @default.
• W2967676574 cites W2219662516 @default.
• W2967676574 cites W2225287204 @default.
• W2967676574 cites W2234957484 @default.
• W2967676574 cites W2275877493 @default.
• W2967676574 cites W2323851578 @default.
• W2967676574 cites W2406250479 @default.
• W2967676574 cites W2478891054 @default.
• W2967676574 cites W2559953355 @default.
• W2967676574 cites W2590497374 @default.
• W2967676574 cites W2601943254 @default.
• W2967676574 cites W2606495925 @default.
• W2967676574 cites W2608102145 @default.
• W2967676574 cites W2747207966 @default.
• W2967676574 cites W2765224588 @default.
• W2967676574 cites W2779221466 @default.
• W2967676574 cites W2792807239 @default.
• W2967676574 cites W2793883040 @default.
• W2967676574 cites W2799455970 @default.
• W2967676574 cites W2883867140 @default.
• W2967676574 cites W2890187186 @default.
• W2967676574 cites W2892457226 @default.
• W2967676574 cites W2904211489 @default.
• W2967676574 cites W2947377238 @default.
• W2967676574 doi "https://doi.org/10.3390/cancers11081145" @default.
• W2967676574 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6721568" @default.
• W2967676574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31405063" @default.
• W2967676574 hasPublicationYear "2019" @default.
• W2967676574 type Work @default.
• W2967676574 sameAs 2967676574 @default.
• W2967676574 citedByCount "29" @default.
• W2967676574 countsByYear W29676765742020 @default.
• W2967676574 countsByYear W29676765742021 @default.
• W2967676574 countsByYear W29676765742022 @default.
• W2967676574 countsByYear W29676765742023 @default.
• W2967676574 crossrefType "journal-article" @default.
• W2967676574 hasAuthorship W2967676574A5022500207 @default.
• W2967676574 hasAuthorship W2967676574A5024342569 @default.
• W2967676574 hasAuthorship W2967676574A5034916208 @default.
• W2967676574 hasAuthorship W2967676574A5035608148 @default.
• W2967676574 hasAuthorship W2967676574A5037048847 @default.
• W2967676574 hasAuthorship W2967676574A5044503703 @default.
• W2967676574 hasAuthorship W2967676574A5047645174 @default.
• W2967676574 hasAuthorship W2967676574A5049353036 @default.
• W2967676574 hasAuthorship W2967676574A5053642255 @default.
• W2967676574 hasAuthorship W2967676574A5056804941 @default.
• W2967676574 hasAuthorship W2967676574A5057663273 @default.
• W2967676574 hasAuthorship W2967676574A5080124352 @default.
• W2967676574 hasBestOaLocation W29676765741 @default.
• W2967676574 hasConcept C104317684 @default.
• W2967676574 hasConcept C121608353 @default.
• W2967676574 hasConcept C143998085 @default.
• W2967676574 hasConcept C150194340 @default.
• W2967676574 hasConcept C16930146 @default.
• W2967676574 hasConcept C203014093 @default.
• W2967676574 hasConcept C2776107976 @default.
• W2967676574 hasConcept C2776256026 @default.
• W2967676574 hasConcept C2777701055 @default.
• W2967676574 hasConcept C2779399171 @default.
• W2967676574 hasConcept C2779733811 @default.

• next